Brief: Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120
24/10/2017 14:05
Oct 24 (Reuters) - Sienna Biopharmaceuticals Inc SNNA.O
* Sienna Biopharmaceuticals announces first patient dosed in
phase 2B trial of topical SNA-120
* Sienna Biopharmaceuticals Inc - top-line results expected
in first half of 2019
* Sienna Biopharmaceuticals - phase 2B trial of topical
SNA-120 to enroll about 190 patients with Pruritus associated
with psoriasis
Source text for Eikon: ID:nGNXOGGUGa
Further company coverage: SNNA.O
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Sienna Biopharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Adobe, Oracle, Snap, Phreesia, Sarepta, Aquestive Therapeutics, Patterson-UTI
U.S. STOCKS ON THE MOVE-Lululemon, GE, Starbucks, Delta Air Lines, Lumber Liquidators, Lovesac
Sienna Biopharma: Falls on Nasdaq delisting plans
Brief: Sienna Biopharma Says Bankruptcy Court Approved Sale Of Assets Related To SNA-001 For $1.7 Mln In Cash
Brief: Sienna Biopharmaceuticals Announces Court Approval Of Chapter 11 Bidding Procedures